LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Surface and Global Proteome Analyses Identify ENPP1 and Other Surface Proteins as Actionable Immunotherapeutic Targets in Ewing Sarcoma.

    Mooney, Brian / Negri, Gian Luca / Shyp, Taras / Delaidelli, Alberto / Zhang, Hai-Feng / Spencer Miko, Sandra E / Weiner, Amber K / Radaoui, Alexander B / Shraim, Rawan / Lizardo, Michael M / Hughes, Christopher S / Li, Amy / El-Naggar, Amal M / Rouleau, Melanie / Li, Wei / Dimitrov, Dimiter S / Kurmasheva, Raushan T / Houghton, Peter J / Diskin, Sharon J /
    Maris, John M / Morin, Gregg B / Sorensen, Poul H

    Clinical cancer research : an official journal of the American Association for Cancer Research

    2023  Volume 30, Issue 5, Page(s) 1022–1037

    Abstract: Purpose: Ewing sarcoma is the second most common bone sarcoma in children, with 1 case per 1.5 million in the United States. Although the survival rate of patients diagnosed with localized disease is approximately 70%, this decreases to approximately 30% ...

    Abstract Purpose: Ewing sarcoma is the second most common bone sarcoma in children, with 1 case per 1.5 million in the United States. Although the survival rate of patients diagnosed with localized disease is approximately 70%, this decreases to approximately 30% for patients with metastatic disease and only approximately 10% for treatment-refractory disease, which have not changed for decades. Therefore, new therapeutic strategies are urgently needed for metastatic and refractory Ewing sarcoma.
    Experimental design: This study analyzed 19 unique Ewing sarcoma patient- or cell line-derived xenografts (from 14 primary and 5 metastatic specimens) using proteomics to identify surface proteins for potential immunotherapeutic targeting. Plasma membranes were enriched using density gradient ultracentrifugation and compared with a reference standard of 12 immortalized non-Ewing sarcoma cell lines prepared in a similar manner. In parallel, global proteome analysis was carried out on each model to complement the surfaceome data. All models were analyzed by Tandem Mass Tags-based mass spectrometry to quantify identified proteins.
    Results: The surfaceome and global proteome analyses identified 1,131 and 1,030 annotated surface proteins, respectively. Among surface proteins identified, both approaches identified known Ewing sarcoma-associated proteins, including IL1RAP, CD99, STEAP1, and ADGRG2, and many new cell surface targets, including ENPP1 and CDH11. Robust staining of ENPP1 was demonstrated in Ewing sarcoma tumors compared with other childhood sarcomas and normal tissues.
    Conclusions: Our comprehensive proteomic characterization of the Ewing sarcoma surfaceome provides a rich resource of surface-expressed proteins in Ewing sarcoma. This dataset provides the preclinical justification for exploration of targets such as ENPP1 for potential immunotherapeutic application in Ewing sarcoma. See related commentary by Bailey, p. 934.
    MeSH term(s) Child ; Humans ; Sarcoma, Ewing/genetics ; Sarcoma, Ewing/therapy ; Membrane Proteins ; Proteome ; Proteomics ; Sarcoma ; Bone Neoplasms/genetics ; Bone Neoplasms/therapy ; Immunotherapy ; Antigens, Neoplasm ; Oxidoreductases
    Chemical Substances Membrane Proteins ; Proteome ; STEAP1 protein, human (EC 1.16.1.-) ; Antigens, Neoplasm ; Oxidoreductases (EC 1.-)
    Language English
    Publishing date 2023-10-07
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
    ZDB-ID 1225457-5
    ISSN 1557-3265 ; 1078-0432
    ISSN (online) 1557-3265
    ISSN 1078-0432
    DOI 10.1158/1078-0432.CCR-23-2187
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma.

    Weiner, Amber K / Radaoui, Alexander B / Tsang, Matthew / Martinez, Daniel / Sidoli, Simone / Conkrite, Karina L / Delaidelli, Alberto / Modi, Apexa / Rokita, Jo Lynne / Patel, Khushbu / Lane, Maria V / Zhang, Bo / Zhong, Chuwei / Ennis, Brian / Miller, Daniel P / Brown, Miguel A / Rathi, Komal S / Raman, Pichai / Pogoriler, Jennifer /
    Bhatti, Tricia / Pawel, Bruce / Glisovic-Aplenc, Tina / Teicher, Beverly / Erickson, Stephen W / Earley, Eric J / Bosse, Kristopher R / Sorensen, Poul H / Krytska, Kateryna / Mosse, Yael P / Havenith, Karin E / Zammarchi, Francesca / van Berkel, Patrick H / Smith, Malcolm A / Garcia, Benjamin A / Maris, John M / Diskin, Sharon J

    bioRxiv : the preprint server for biology

    2024  

    Abstract: Cancer immunotherapies have produced remarkable results in B-cell malignancies; however, optimal cell surface targets for many solid cancers remain elusive. Here, we present an integrative proteomic, transcriptomic, and epigenomic analysis of tumor ... ...

    Abstract Cancer immunotherapies have produced remarkable results in B-cell malignancies; however, optimal cell surface targets for many solid cancers remain elusive. Here, we present an integrative proteomic, transcriptomic, and epigenomic analysis of tumor specimens along with normal tissues to identify biologically relevant cell surface proteins that can serve as immunotherapeutic targets for neuroblastoma, an often-fatal childhood cancer of the developing nervous system. We apply this approach to human-derived cell lines (N=9) and cell/patient-derived xenograft (N=12) models of neuroblastoma. Plasma membrane-enriched mass spectrometry identified 1,461 cell surface proteins in cell lines and 1,401 in xenograft models, respectively. Additional proteogenomic analyses revealed 60 high-confidence candidate immunotherapeutic targets and we prioritized Delta-like canonical notch ligand 1 (DLK1) for further study. High expression of DLK1 directly correlated with the presence of a super-enhancer spanning the DLK1 locus. Robust cell surface expression of DLK1 was validated by immunofluorescence, flow cytometry, and immunohistochemistry. Short hairpin RNA mediated silencing of DLK1 in neuroblastoma cells resulted in increased cellular differentiation. ADCT-701, a DLK1-targeting antibody-drug conjugate (ADC), showed potent and specific cytotoxicity in DLK1-expressing neuroblastoma xenograft models. Moreover, DLK1 is highly expressed in several adult cancer types, including adrenocortical carcinoma (ACC), pheochromocytoma/paraganglioma (PCPG), hepatoblastoma, and small cell lung cancer (SCLC), suggesting potential clinical benefit beyond neuroblastoma. Taken together, our study demonstrates the utility of comprehensive cancer surfaceome characterization and credentials DLK1 as an immunotherapeutic target.
    Highlights: Plasma membrane enriched proteomics defines surfaceome of neuroblastomaMulti-omic data integration prioritizes DLK1 as a candidate immunotherapeutic target in neuroblastoma and other cancersDLK1 expression is driven by a super-enhancer
    Language English
    Publishing date 2024-01-07
    Publishing country United States
    Document type Preprint
    DOI 10.1101/2023.12.06.570390
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top